InterventionsHuman trial546 participants48 weeks

Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension

Figure 1 from American Journal of Preventive Cardiology
Open the figure at full size
Figure 1Laffin et al.

American Journal of Preventive Cardiology

The paper

Cleveland Clinic · Eli Lilly (United States)

American Journal of Preventive Cardiology · 6 Aug 2026

doi.org/10.1016/j.ajpc.2026.101783PubMed 42830762

More on GLP1R